Aura Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$1.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Phase 3 CoMpass Trial Enrollment Status QuarterlyTarget: 100% Enrolled (Completed)
Cash Runway (Years) Quarterly2.0Target: Fund operations into the second half of 2028
Phase 1b/2 NMIBC Trial 3-Month Clinical Data Progress QuarterlyTarget: Initial 3-month clinical data expected mid-2026
Watch Items
- Topline data readout for Phase 3 CoMpass trial in early choroidal melanomaTrigger: 15-month primary endpoint evaluationAction: Review efficacy (vision preservation and tumor control) and safety profiles to support regulatory filing
- Initial 3-month clinical data from Phase 1b/2 NMIBC trialTrigger: Mid-2026 data releaseAction: Evaluate immune ablative and neoadjuvant efficacy of bel-sar in non-muscle invasive bladder cancer
- Early proof-of-concept data for choroidal metastasesTrigger: Late 2026 data releaseAction: Assess safety and early efficacy based on a four-week endpoint to validate non-ocular solid tumor expansion
Research as of 19 Jun 2026